Dotmatics’ Principal Consultant Featured in Scientific Computing World
Dotmatics’ Principal Consultant Dan Ormsby highlighted in Scientific Computing World how applying domain knowledge to AI-prepared data, particularly in small molecule drug discovery and lead optimization, enhances feature engineering to yield more meaningful and interpretable results, thereby driving new research areas and competitive advantages for early AI adopters.
An AI Revolution
In September 2021, Robert Roe reported on how the use of AI is driving new areas of research and increasing the competitiveness of early adopters.
“Generating and transforming data to be AI-ready is just one step in the process. Applying domain knowledge to data allows the algorithms to only focus on important features in your data, increasing the chance of meaningful and interpretable results.
I’ve started my feature engineering work by focusing on small molecule drug discovery, such as lead optimization. Dotmatics has many customers with workflows in that area, so you can imagine the level of domain knowledge we can help each to bring to their data.”
– Dan Ormsby, PhD, Principal Consultant at Dotmatics
Related
CBS News: How AI Is Accelerating Safer, More Personalized Drug Discovery
In a CBS News interview, Dotmatics VP Phil Mounteney explains how their internally developed AI models accelerate drug discovery by analyzing early-phase research data to shorten development cycles, reduce costs, and deliver safer, personalized therapies while maintaining data privacy.
Four Moves Biotechs Can Make to Stay Competitive as Investor Confidence Shifts
As investor confidence in biotech has shifted from rapid, high-risk funding to more cautious, data-driven investment with longer timelines and stricter demands, biotechs must adapt by embracing innovative R&D platforms, demonstrating clear value through validated data and milestones, exploring flexible partnership models like co-development and joint ventures, and strategically managing growth to remain competitive in a market with tighter capital and evolving investor expectations.
The Rise of Biotech: Why Smaller Companies Are Outpacing Big Pharma on Innovation
Smaller biotech companies are increasingly outpacing big pharmaceutical firms in new molecular entity approvals due to their greater agility, willingness to take risks, and freedom to innovate despite funding challenges, with over half of upcoming blockbuster drug launches expected from first-time launchers who face higher risks but also potential for significant success.
CIO.Inc: Can AI Finally Close the Gap Between Science and Software?
Alister Campbell, VP at Dotmatics, explains in CIO.Inc how AI is addressing the longstanding "last mile" challenge of translating scientific models into scalable software applications, enabling faster, more cost-effective development of personalized medicines and potentially revolutionizing patient access to safer therapeutics.
NBC News: How AI is Transforming Drug Discovery
In an NBC News segment, Alister Campbell, VP of Dotmatics, explains how the company leverages AI to analyze large datasets, predict effective drug compounds, and streamline fragmented data systems and manual workflows, thereby accelerating and improving the efficiency of drug discovery.
Leveraging Informatics and Modeling Tools to Develop a Comprehensive Design Make and Test Platform
LifeArc, a UK medical research charity focused on developing diagnostics and therapeutics for diseases like cancer and autoimmune disorders, utilizes the Dotmatics Platform to integrate and streamline their entire Design-Make-Test research cycle by uniting internal and external collaborators, automating data acquisition, and providing seamless access to predictive modeling, informatics, and AI/ML tools for small molecule and antibody discovery while protecting intellectual property.